FormulaFolio Investments LLC cut its holdings in Becton Dickinson and Co (NYSE:BDX) by 73.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 849 shares of the medical instruments supplier’s stock after selling 2,318 shares during the quarter. FormulaFolio Investments LLC’s holdings in Becton Dickinson and were worth $212,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc raised its holdings in shares of Becton Dickinson and by 1.3% in the third quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after purchasing an additional 283,433 shares during the last quarter. BlackRock Inc. grew its position in shares of Becton Dickinson and by 1.9% in the fourth quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after purchasing an additional 355,223 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of Becton Dickinson and by 22,485.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares during the period. Ronna Sue Cohen grew its position in shares of Becton Dickinson and by 24,129.0% in the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after purchasing an additional 5,710,365 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Becton Dickinson and by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock valued at $1,103,526,000 after purchasing an additional 416,459 shares during the period. 84.58% of the stock is currently owned by hedge funds and other institutional investors.
In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total value of $687,836.82. Following the completion of the sale, the executive vice president now owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Samrat S. Khichi sold 16,085 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total value of $3,774,827.80. Following the completion of the sale, the executive vice president now directly owns 12,608 shares of the company’s stock, valued at approximately $2,958,845.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,154 shares of company stock valued at $4,955,775. Insiders own 0.12% of the company’s stock.
Shares of BDX stock traded down $2.88 on Friday, reaching $234.16. 984,241 shares of the company’s stock traded hands, compared to its average volume of 1,268,337. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $63.79 billion, a price-to-earnings ratio of 21.27, a P/E/G ratio of 1.75 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. Becton Dickinson and’s revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.65 earnings per share. On average, sell-side analysts predict that Becton Dickinson and Co will post 11.69 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be given a dividend of $0.77 per share. The ex-dividend date is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.32%. Becton Dickinson and’s payout ratio is 27.97%.
A number of equities research analysts have recently commented on the company. UBS Group lowered their price objective on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, May 10th. Wells Fargo & Co lowered their target price on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a report on Monday, May 13th. BMO Capital Markets lowered their target price on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a report on Friday, May 10th. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, April 1st. Finally, Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $255.31.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Intrinsic Value
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.